REVIEW article

Front. Immunol., 28 April 2025

Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders

Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1492726

Systemic lupus erythematosus and atherosclerosis: immune pathways and the uncharted territory of gut microbiota and metabolism

  • 1. Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Non-communicable Diseases, Clinical Research and Experimental Center, Department of Nephrology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China

  • 2. Laboratory of Cardiovascular Diseases, Cardiovascular Medicine Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China

  • 3. Department of Clinical Laboratory, State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

Abstract

Patients with Systemic Lupus Erythematosus (SLE) are significantly more susceptible to atherosclerosis, which may elevate their mortality risk. The review explores recent understandings of the origins and remedies for atherosclerosis associated with SLE. Our focus is particularly on the consequences of immune system disparities, interruptions in intestinal bacteria, and metabolic complications. The influence of SLE on atherosclerosis extends past usual risk elements, including processes specific to the disease. The list encompasses excessive immune cell activity, production of autoantibodies, inflammatory responses. A variety of therapies for atherosclerosis linked to SLE encompass cholesterol-lowering medications, anti-inflammatory drugs, immune suppressors, antimalarials, interferon treatments, NET inhibitors, and methods aimed at T and B-cells. However, existing research has its shortcomings, necessitating additional clinical trials to ascertain the efficacy and security of these therapies. The direct interactions among SLE, gut microbiota, metabolism, and atherosclerosis is underexplored, presenting innovation opportunities. Research into specific gut microbial strains and metabolites’ effects on immune responses and atherosclerosis progression in SLE patients is needed. Such research could uncover novel therapeutic targets and biomarkers, advancing prevention and treatment strategies for SLE cardiovascular complications.

1 Introduction

Patients with systemic lupus erythematosus (SLE) face an elevated risk of cardiovascular diseases (CVDs), particularly atherosclerosis (AS), driven by both traditional and SLE-specific factors. Traditional risk factors such as dyslipidemia, hypertension, and smoking interact with SLE-related pathological mechanisms, including chronic inflammation, immune dysregulation (, ).

Macrophages contribute to vascular injury through oxidized low-density lipoprotein (ox-LDL) uptake and foam cell formation (). Type I interferons (IFNs) enhance neutrophil extracellular traps (NETs) release, exacerbating endothelial dysfunction (, ). CXCR3+ T helper 1 (Th1) cells migrate to arterial walls, promoting vascular inflammation, while B cells drive atherosclerosis via autoantibody production (e.g., anti-endothelial cell antibodies) and immune complex deposition (–).

Pro-inflammatory gut microbiota elevate systemic inflammation (, ), and dietary L-carnitine conversion to trimethylamine N-oxide (TMAO) by Emergencia timonensis accelerates atherosclerosis in mice and humans (). SLE patients exhibit gut dysbiosis characterized by reduced beneficial bacteria and increased pathogenic species (, ). However, direct evidence linking gut microbiota or metabolites to SLE-associated atherosclerosis remains sparse, highlighting the need for further research.

We have focused on discussing immune-targeted therapies (e.g., interferon inhibitors (), T-cell (), and B-cell therapies ()) and inflammatory pathways. Emerging approaches modulating gut microbiota or metabolites (e.g., TMAO inhibitors) show preclinical potential to attenuate plaque inflammation, though clinical validation in SLE remains scarce (). This underexplored axis offers novel therapeutic opportunities.

This review aims to offer novel insights and new research directions for atherosclerosis associated with SLE. Current therapeutic strategies for SLE-related atherosclerosis prioritize immune balance restoration (e.g., interferon inhibition and T/B-cell modulation). Simultaneously, targeting gut microbiota dysbiosis and metabolites like TMAO emerge as promising adjunct approaches to ameliorate both autoimmune dysregulation and atherosclerosis in SLE. Integrating these dual pathways may pioneer synergistic therapies to reduce cardiovascular burden in SLE patients.

2 The role of immune imbalance in the pathogenesis of SLE-related atherosclerosis

2.1 Pro-inflammatory environment, oxidative stress, and macrophage dysfunction

The pro-inflammatory environment, oxidative stress, and macrophage dysfunction constitute key mechanisms driving SLE-related atherosclerosis (Figure 1). SLE, characterized by chronic inflammation, induces endothelial cell damage and dysfunction (). Pro-inflammatory cytokines (e.g., TNF-α, IFN-γ) upregulate endothelial adhesion molecules, facilitating monocyte-laden leukocyte migration into the vascular intima (). Patients with SLE exhibit a distinct “lupus lipoprotein pattern” with reduced high-density lipoprotein (HDL) and elevated low-density lipoprotein (LDL), total cholesterol, and triglycerides (). This lipid profile synergizes with chronic inflammation to promote vascular injury and plaque initiation (). Oxidative stress, defined by reactive oxygen species (ROS) overproduction, critically accelerates AS pathogenesis (). ROS increase vascular permeability (), and convert LDL to oxidized LDL (oxLDL) that accumulates subendothelially (). Key enzymes like myeloperoxidase (MPO) and NADPH oxidase (NOX) are involved in this oxidative process. Oxidized LDL (oxLDL) is particularly critical in atherosclerosis, inducing inflammation through scavenger and Toll-like receptors (TLR) (). OxLDL promotes the migration of monocytes towards the vascular endothelium and facilitating monocyte chemotaxis and adhesion through interactions between surface molecules like CD36 on monocytes and endothelial adhesion molecules such as vascular Cell Adhesion Molecule-1 (VCAM-1) and Intercellular Adhesion Molecule-1 (ICAM-1) ().

Figure 1

Macrophage SRs (CD36, SR-A1, LOX-1) mediate oxLDL uptake, forming foam cells essential for AS progression (, ). M1 macrophages with high CD36/SR-A1 expression dominate early lesions (), whereas M2 counterparts with reduced LOX-1 and elevated IL-10/TGF-β secretion exert protective effects (). In SLE, IFN-α-induced SR-A1 overexpression () combined with elevated LDL () exacerbates foam cell formation. Patient-specific SR expression patterns modulate oxLDL clearance efficiency and inflammatory responses (). Macrophage-T cell crosstalk in plaques sustains cytokine-driven inflammation (). Polarization dynamics determine plaque fate: M1-derived pro-inflammatory mediators destabilize plaques (), while M2 macrophages promote stabilization (). oxLDL-driven M1 polarization predominance underlies SLE-accelerated AS ().

The buildup of lipids, immune cells, and debris along with extracellular matrix (ECM) degradation and rising inflammation promotes unstable plaque development (). vascular smooth muscle cell (VSMC)-mediated fibrous cap formation stabilizes plaques through ECM reinforcement (). Neutrophil-induced endothelial injury disrupts this process, increasing thrombosis risk (). Chronic SLE inflammation synergizes with traditional risk factors to create self-perpetuating cycles of plaque expansion/rupture, culminating in myocardial infarction or stroke (). Therefore, targeting the oxidative stress-macrophage polarization axis may break this vicious cycle in SLE-associated AS.

2.2 Type I IFN response

Type I interferons (IFN-I) are crucial in the development of SLE-Related AS, as depicted in Figure 2. In SLE, IFN-I production originates from dendritic cells, neutrophils, and monocytes/macrophages (), encompassing thirteen IFN-α subtypes, IFN-β, and rare variants (IFN-ϵ, IFN-κ, IFN-ω) (). Over 60% of SLE patients demonstrate an “IFN signature” characterized by elevated IFN-regulated gene activity, with nearly 50% exhibiting sustained high IFN-I levels linked to genetic predisposition and enhanced disease risk (). Defective apoptosis in SLE increases extracellular DNA/RNA that complexes with anti-DNA/RNA antibodies to form immune complexes (ICs) (). ICs activate plasmacytoid dendritic cells (pDCs), which are primary IFN-I producers in SLE (). pDCs recognize DNA and RNA in immune complexes via TLR9 and TLR7, triggering myeloid differentiation factor 88 (MyD88) and downstream signaling through nuclear factor kappa B (NF-κB) and Mitogen-activated protein kinases (MAPKs) (). Subsequent nuclear translocation of interferon regulatory factor 7 (IRF7) triggers IFN-I transcription via binding to interferon-stimulated response element (ISRE) promoters (, ). Autocrine amplification occurs through IFNAR-mediated JAK kinase (TYK2/JAK1) activation, inducing STAT1/2 phosphorylation and ISGF3 complex formation that enhances interferon-stimulated genes (ISGs) expression ().

Figure 2

IFN-I-induced endothelial cell damage and repair-imbalance accelerate atherosclerosis (). In SLE, IFN-α significantly exacerbates atherosclerosis by modulating endothelial progenitor cells (EPCs) and bone marrow-derived circulating angiogenic cells (CACs) (). This modulation includes inducing EPC apoptosis, which negatively impacts their number, structure, and function, thus impairing vascular repair (). Furthermore, IFN-α inhibits vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) activities, hindering neovascularization and repair (). Inhibiting the IFNAR reverses EPC/CAC dysfunction in SLE, restoring angiogenic potential (). In NZM-2328 mice, IFN-α worsens reduced endothelial function and EPC/CAC levels, which IFNAR knockout prevents ().

Concurrently, IFN-α creates anti-angiogenic microenvironments via IL-1 pathway dysregulation (reduced IL-1α/1β/1R1; elevated IL-1Ra/1R2) that JAK inhibitors effectively counteract (). IFN-I further induces pro-atherogenic cytokines like IL-18, exacerbating vascular injury and AS progression in SLE (). In conclusion, Type I interferons play a crucial role in SLE, influencing immune responses and vascular damage.

2.3 Neutrophils and neutrophil extracellular traps

Neutrophils play a key role in SLE-related AS development by enhancing the IFN-I signature and NET formation, as shown in Figure 3. NETs are characterized by large, web-like structures composed of chromatin, histones, and proteins (). The formation of these structures depends on ROS produced by NOX and/or mitochondrial ROS. Additionally, the activation of peptidyl arginine deiminase (PAD) and MPO converts arginine to citrulline, leading to chromatin decondensation ().

Figure 3

Low-density granulocytes (LDGs), a pro-inflammatory neutrophil subset, drive spontaneous NET release that induces endothelial dysfunction and vascular injury in SLE-associated AS (). These cells overproduce TNF-α and IFN-I (), while their NETs deliver autoantigens that perpetuate autoimmune responses (). LDG-derived NETs activate T-cells () and transfer matrix metalloproteinase 9 (MMP9) to endothelial cells, triggering MMP2-mediated apoptosis (). NET-associated small RNAs promote endothelial inflammation through TLR signaling (, ), whereas LL-37 (a cathelicidin peptide) stabilizes NET-DNA complexes and enhances plasmacytoid dendritic cell (pDC)-mediated IFN-α production (, ). Concurrently, oxidized mitochondrial DNA (ox-mtDNA) in NETs activates the cyclic GMP-AMP synthase - stimulator of interferon genes (cGAS-STING) pathway, amplifying IFN-I responses (, ). Impaired NET clearance in SLE, attributed to anti-DNase I antibodies (), allows persistent High Mobility Group Box 1 (HMGB1) release that exacerbates chemotaxis and cytokine storms (, ).

NETs further sustain vascular inflammation via macrophage inflammasome activation and IL-18-driven NETosis (), establishing an IFN-I-NET positive feedback loop that accelerates AS (, ). NOX, nitric oxide synthase (NOS), and MPO within NETs oxidize HDL, impairing cholesterol efflux and promoting foam cell formation (). Collectively, neutrophil-derived NETs emerge as central mediators of SLE-related AS through multifaceted immune activation and vascular injury mechanisms.

2.4 T-cell dysfunction

T-cell dysfunction is essential in the development of AS in SLE patients, as shown in Figure 4. In SLE, CD4+ T-cells exhibit hyperactivation with reduced activation thresholds (), where pDC-derived IFN-I induces endothelial cell production of CXCR3 ligands (CXCL9), promoting CD4+CXCR3+ T-cell arterial infiltration (). Additionally, CD4+CCR5+ T-cells accumulate in SLE patients with carotid AS, demonstrating CCR5-mediated plaque homing (). These CXCR3+ (tissue migration) and CCR5+ (plaque recruitment) subsets synergistically accelerate AS through complementary pathways (, ), independent of traditional risk factors like dyslipidemia ().

Figure 4

Follicular helper T-cells (Tfh) exacerbate AS via major histocompatibility complex II (MHCII)-dependent B-cell differentiation into IgG-secreting plasma cells (, ), while cTfh1/cTfh2/cTfh17 subpopulations interact with neutrophils to amplify vascular inflammation (). Cholesterol-rich environments enhance splenic B-cell control over Tfh expansion through programmed death ligand 1 (PD-L1) regulation ().

Imbalanced regulatory T-cell (Treg)/effector T-cell (Teff) ratios correlate with AS progression (, ). Dyslipidemia and elevated T-cell Pbx1d levels can intensify autoimmune reactions and atherosclerosis by disrupting Treg stability (). Dyslipidemia-induced Pbx1d overexpression destabilizes Tregs, diminishing IL-10 and FoxP3 expression (). Conversely, expanded Th17 cells secrete IL-17 to enhance plaque inflammation (, 67), while Th1 and cytotoxic CD8+ T-cells directly damage endothelium via cytokine release (, 68). Circulating IFN-Ihi CD4+ and exhausted/activated CD8+ T-cells infiltrate SLE vascular lesions (, 69).

Other T-cell subsets, such as CD3+CD31+CXCR4+angiogenic T-cells (Tang), aid vascular endothelium repair during AS (70). However, in SLE patients, especially those positive for anti-dsDNA, elevated CD8+Tang cell levels in blood may signal endothelial damage and cardiovascular risks (71). The expanded CD28(null)Tang subset, associated with aging, intensifies endothelial inflammation via inflammatory factor release, leading to atherosclerosis and linked to SLE disease activity (72, 73). Invariant natural killer T (iNKT) cells lose early anti-AS capacity due to impaired CD1d-mediated lipid presentation (74, 75).

Metabolically reprogrammed CD4+ T-cells exhibit enhanced glycolysis via pyruvate kinase M2 (PKM2) activation, releasing pro-inflammatory cytokines (76). IFN-I disrupts T-cell bioenergetics (77), creating self-perpetuating inflammatory loops that pharmacological inhibition can reverse (78). Collectively, T-cell-mediated immunity constitutes a central axis in SLE-associated AS pathogenesis.

2.5 B-cell dysfunction

B-cells and their autoantibodies are key in SLE-induced AS, as shown in Figure 4. Elevated anti- HDL, paraoxonase 1 (PON1), and apolipoprotein A1 (apoA1) antibodies serve as progression markers (79, 80), with anti-HDL predicting cardiovascular risk and anti-PON1 correlating with intimal thickening (80). Patients with SLE exhibit reduced IgM/IgG anti-phosphocholine (PC) levels inversely associated with AS severity (81–85), where IgM anti-PC mitigates disease activity while IgG anti-PC inhibits endothelial adhesion molecules (83–85). Hyperlipidemia-driven B-cell activation promotes oxLDL generation (86, 87), further amplified by ICs containing ribonucleoproteins and anti-Ro/La antibodies that enhance anti-oxLDL production (88). OxLDL-β2-glycoprotein I complexes stimulate foam cell formation and autoantibody responses (89).

B-cell-activating factor (BAFF) elevation correlates with subclinical AS (90), while B1 cells paradoxically exhibit both protective (autoimmunity suppression) and pathogenic (class-switched IgG production) roles (91, 92). Lupus-prone mice demonstrate marginal zone B cell-driven pathogenic antibody secretion (93) and abnormal plasma cell differentiation involving somatic hypermutation (94). Pathogenic autoantibodies include anti-dsDNA (endothelial dysfunction/thrombosis induction) (95, 96), anti-endothelial cell antibodies (IgA-mediated vascular injury) (97, 98), and antiphospholipid antibodies (plaque progression in 20-30% patients) (99).

Protective autoantibodies counterbalance these effects: anti-oxLDL-IgM, anti-ApoB100, anti-PC, and anti-malondialdehyde (MDA) antibodies suppress oxLDL uptake and foam cell formation (100, 101). Reduced anti-ApoB100 levels in SLE imply impaired AS protection (101), while anti-C1q antibodies promote M2 macrophage polarization (102). Anti-PC-IgM modulates Treg/Th17 equilibrium, synergizing with anti-MDA-IgM for cardiovascular protection (84, 103). Nevertheless, dietary/metabolic constraints limit their therapeutic potential in SLE (104). Collectively, B-cell-derived autoantibody networks constitute pivotal drivers of SLE-associated AS.

3 The role of gut microbiota dysbiosis and metabolic disorders in the pathogenesis of atherosclerosis

Gut microbiota dysbiosis and metabolites (e.g., TMAO) are well - known to promote atherosclerosis via inflammatory pathways and immune dysregulation in various diseases, although their direct role in SLE associated atherosclerosis remains unclear. There are numerous studies exploring the relationships between SLE and gut microbiota, or between atherosclerosis and gut microbiota, and also between metabolic disorders and both of them. However, research comprehensively integrating SLE, atherosclerosis, gut microbiota, and metabolic disorders remains unexplored. While Cabana-Puig et al. (105) demonstrated high-fat diet (HFD) exacerbates atherosclerosis via Ly6C+ monocyte pathways and Lactobacillus improves glomerulonephritis, these interventions were examined independently. Thus, this study does not establish causal relationships between gut microbiota and SLE-associated atherosclerosis. This underscores the critical need for integrated investigations examining microbiome-atherosclerosis interactions specifically in SLE contexts.

In this section, considering the current state of research, we mainly focus on the general mechanisms by which gut microbiota dysbiosis and metabolic disorders lead to atherosclerosis (including in diseases other than SLE), as depicted in Figure 5.

Figure 5

3.1 Genetic factors

The gut microbiota significantly influences the development of atherosclerosis, with genetic factors playing an important role. A study showed that proinflammatory gut microbiota from Caspase1-/- mice accelerated atherosclerosis in Ldlr-/- mice, as evidenced by increased levels of circulating monocytes, neutrophils, and proinflammatory cytokines. Fecal microbiota transplantation reduced short-chain fatty acid-producing taxa, such as Akkermansia and Clostridium, leading to decreased anti-inflammatory short-chain fatty acids in the cecum (). This study highlights the multifaceted interplay between gut microbiota, genetic factors, and atherosclerosis.

3.2 Specific microbiota promotes atherosclerosis progression

Bacterial DNA in atherosclerotic plaques suggests intestinal bacteria can migrate to the vascular system, as seen with Streptococcus spp. moving to coronary artery plaques, leading to elevated pro-inflammatory cytokines and altered vascular tension, which contribute to coronary atherosclerosis (106, 107). Mechanistically, Desulfovibrio desulfuricans compromises intestinal barrier integrity, enabling lipopolysaccharide (LPS) translocation that activates the TLR4/NF-κB inflammatory axis (108). Circulating LPS subsequently recruits inflammatory cells to lesions through LPS-binding protein (LBP)/TLR4 signaling (109). Conversely, Faecalibacterium prausnitzii fortifies gut barriers and suppresses LPS synthesis, mitigating coronary artery disease (CAD) risk (110). Comparative studies reveal divergent microbial impacts: Porphyromonas gingivalis oral infection exacerbates atherosclerosis in ApoE-/- mice via gut dysbiosis and lipid abnormalities (reduced HDL/triglycerides) (111), while Bacteroides fragilis-induced dysbiosis (decreased Lactobacillaceae; increased Desulfovibrionaceae) promotes plaque formation through metabolic inflammation (). Transplant experiments using Caspase1-/- mouse microbiota demonstrate accelerated atherosclerosis in Ldlr-/- recipients through systemic inflammation and microbial community shifts (). These findings establish the gut-vascular axis as a multidimensional crosstalk involving barrier regulation, immunometabolic reprogramming, and microbial ecosystem remodeling.

3.3 TMAO as a promoter of atherosclerosis

TMAO accelerates atherosclerosis via multiple mechanisms. Gut microbes process dietary choline/carnitine/betaine into trimethylamine (TMA) using cut/cnt enzymes, with liver FMO3 converting TMA to TMAO (112). TMAO activates NF-κB to increase inflammatory cytokines for plaque formation (113), triggers NLRP3 inflammasome via SIRT3-SOD2-mtROS in endothelial cells (114), and enhances macrophage CD36/SR-A1-mediated ox-LDL uptake causing foam cell formation (115). It also suppresses bile acid synthesis through FXR/SHP receptors, impairing cholesterol excretion (116).

Gut microbiota directly modulates TMAO’s atherogenic effects. Lachnoclostridium saccharolyticum converts choline to TMA, correlating with plaque growth (117). Emergencia timonensis uniquely processes l-carnitine-derived γ-butyrobetaine into TMA (). PSRC1 deficiency elevates TMAO and worsens atherosclerosis in ApoE-/- mice through gut dysbiosis (112).

Current research on TMAO in SLE remains limited. While TMAO’s pro-atherogenic mechanisms are well-characterized in other diseases (112–118), its specific role in SLE-related cardiovascular complications requires cautious interpretation given the limited disease-specific evidence. Clinical studies have demonstrated elevated plasma TMAO levels in lupus patients compared to healthy controls (119). González-Correa et al. () demonstrated that TMAO exacerbates vascular endothelial dysfunction via oxidative stress and impaired antioxidant defense in TLR7-activated lupus mice. Their intervention with 3,3-dimethyl-1-butanol (DMB), a TMA production inhibitor, effectively reduced circulating TMAO levels and alleviated hypertension in this lupus mouse model ().

In conclusion, gut microbiota promotes TMAO production, which critically drives atherosclerosis through inflammatory and metabolic mechanisms (112–118). In lupus mice, TMAO causes vascular dysfunction that may accelerate atherosclerosis in SLE, but this connection requires further investigation. It should be emphasized that González-Correa et al. () specifically demonstrated TMAO’s contribution to vascular endothelial dysfunction in TLR7-activated SLE mice, but did not investigate atherosclerosis endpoints. To our knowledge, no published studies have directly examined TMAO’s effects on atherogenesis in lupus models or other systemic autoimmune diseases.

3.4 Tryptophan metabolism disruption

Recent studies have highlighted the role of tryptophan metabolism disruption in promoting atherosclerosis. A study showed that indoleamine 2,3-dioxygenase 1 (IDO1) promotes atherosclerosis by inhibiting IL-10 production, which activates a cAMP-dependent pathway and suppresses Erk1/2 phosphorylation, leading to increased plaque instability (120). Similarly, Laurans et al. found that IDO1 activity in obese mice disrupts the intestinal mucosal barrier, triggers chronic inflammation, and interferes with lipid metabolism, worsening obesity-related metabolic diseases (121). Additionally, Xue et al. identified a protective role for the gut microbial metabolite indole-3-propionic acid (IPA), which reduces plaque development by promoting reverse cholesterol transport in macrophages via the miR-142-5p/ABCA1 signaling pathway (122). These findings highlight the complex relationship between tryptophan metabolism and atherosclerosis.

3.5 Immune dysregulation

Recent research has highlighted the complex interactions between immune responses and gut microbiota in atherosclerosis development. One study found that under hyperlipidemic conditions, gut microbiota can activate B2 cells in perivascular adipose tissue, leading to increased IgG production and disease progression. Disrupting the gut microbiota with broad-spectrum antibiotics or depleting B2 cells pharmacologically mitigated atherosclerosis, emphasizing the role of B2 cells beyond lipid metabolism (123). Another study showed that immunization against gut bacterial outer membrane proteins reduced systemic inflammation and improved metabolic markers in mice fed a Western diet, mediated by apoE, suggesting a potential therapeutic approach for immune-metabolic diseases (124). Dietary modulation critically impacts this axis: high-fat/low-fiber diets induce microbial dysbiosis that amplifies mesenteric lymph node lymphocyte proliferation and accelerates plaque formation (125, 126).These findings underscore the importance of gut microbiota-immune interactions in atherosclerosis, offering insights into therapeutic strategies targeting the gut microbiome.

4 Therapeutic strategies for SLE-related atherosclerosis

4.1 Statins

Statins, cornerstone therapeutics for hyperlipidemia management, have garnered significant attention for their putative role in SLE-associated AS. Through HMG-CoA reductase inhibition, these agents inhibit cholesterol synthesis and ameliorate SLE-associated dyslipidemia—a pivotal atherosclerosis driver (, 127). Preclinical studies demonstrate statins’ dual capacity to attenuate autoimmune activation and atherosclerotic progression (127), exerting anti-atherogenic effects through IL-6/IL-8/TNF-α suppression (, 128). Clinical applications in SLE remain contentious (129): while observational data suggest cardiovascular risk reduction (130), the Lupus Atherosclerosis Prevention Study revealed no significant coronary artery or endothelial improvement after 24-month intervention (131). Current evidence thus indicates that despite plausible mechanistic benefits, statins’ clinical efficacy in SLE-related AS lacks robust validation, necessitating mechanistic investigations to delineate disease-specific pharmacodynamics and optimize therapeutic strategies.

4.2 Glucocorticoids

Glucocorticoids, cornerstone therapeutics for SLE, suppress inflammation and modulate atherogenesis through cytokine reduction (132, 133). Low-dose regimens (e.g., dexamethasone) demonstrate plaque-stabilizing effects (132, 133). However, dose-dependent cardiovascular risks emerge with prolonged high-dose administration, paradoxically accelerating plaque formation (133, 134). This bidirectional relationship necessitates strict adherence to minimal effective dosing with timely tapering to optimize risk-benefit ratios. Notably, chronic high-dose exposure elevates cardiovascular mortality in long-term treated cohorts, demanding vigilant monitoring (134). In conclusion, glucocorticoids should be administered with caution in SLE treatment, alongside other therapies, to balance their anti-inflammatory effects with the need to reduce cardiovascular hazards.

4.3 Immunosuppressant

Mycophenolate mofetil (MMF) and cyclophosphamide (CPA) demonstrate dual therapeutic potential in SLE-atherosclerosis pathogenic nexus. Preclinical evidence reveals MMF alleviates SLE manifestations and atherogenesis via inosine monophosphate dehydrogenase inhibition, curtailing lymphocyte-mediated inflammation (135). CPA exerts immunomodulatory effects through DNA synthesis disruption and lymphocyte clonal expansion blockade, synergistically attenuating plaque development (136). Clinical observations indicate MMF improves cardiovascular risk profiles in SLE cohorts (137, 138), though disease-specific clinical validation remains pending (139). While these immunosuppressants show mechanistic promise in atherosclerotic lesion regression, translating preclinical efficacy into optimized human SLE therapeutics requires systematic investigation of tissue-specific pharmacodynamics and long-term vascular outcomes.

4.4 Antimalarial drugs

The antimalarial agent hydroxychloroquine (HCQ) serves as a cornerstone therapy for SLE and its atherosclerotic complications. HCQ modulates SLE-associated atherogenesis through AP-1-mediated T-cell suppression (140) and endothelial stabilization via dual mechanisms: attenuation of TLR signaling and ROS generation, and AMPK-dependent VSMC cycle arrest (140, 141). Intriguingly, HCQ synergizes with high-dose statins to inhibit cholesterol biosynthesis through precursor regulation without altering serum cholesterol profiles (142). Multicenter clinical data validate its cardioprotective efficacy, demonstrating reductions in cholesterol levels, thrombotic events, and mortality rates in SLE cohorts (143). Extended analyses reveal 30% lower cardiovascular disease risk with HCQ use, particularly regarding CAD and cerebrovascular events (144, 145). These findings position HCQ as a dual-purpose therapeutic agent that concurrently addresses autoimmune dysregulation and vascular pathology in SLE management.

4.5 Therapeutic potential of interferon and NET inhibitors

IFN-I and NETs play a significant role in SLE-related AS, making them potential therapeutic targets. Anifrolumab, a monoclonal antibody, effectively treats moderate to severe SLE by blocking the type I interferon receptor, reducing NET formation, and lowering inflammatory cytokines (146). PADs—key enzymatic drivers of NET formation—show therapeutic promise by downregulating IFN-I signaling cascades in SLE-related AS (147). Janus kinase inhibitors (JAKi) including tofacitinib and baricitinib modulate SLE pathogenesis via JAK/STAT pathway inhibition, with preclinical evidence revealing tofacitinib’s dual capacity to reduce NET burden and restore endothelial homeostasis in MRL/lpr models (148–150). Early-phase clinical trials validate JAKi safety profiles and cardiometabolic benefits (149), while ruxolitinib extends this therapeutic spectrum in murine lupus (148). The TYK2 allosteric inhibitor deucravacitinib achieves comparable IFN-I suppression, with Phase II trials confirming both safety and clinical improvement in SLE cohorts (, ). Collectively, IFN-α antibodies and signaling inhibitors represent mechanistically grounded strategies for SLE-associated AS management, though definitive clinical validation requires large-scale trials to establish risk-benefit ratios across diverse patient populations.

4.6 Targeted T-cell therapy

The abnormal activation of T-cells plays an important role in atherosclerosis associated with SLE (67). For patients with SLE, Th17 cells exacerbate atherosclerosis advancement by generating inflammatory substances like IL-17 (). Simultaneously, Tregs slow down atherosclerosis development by inhibiting effector T-cells and fostering anti-inflammatory reactions (151).

Notably, low-dose IL-2 selectively modulates the balance among Treg, Tfh, and Th17 cells, effectively reducing SLE disease activity and improving clinical outcomes while showing high tolerability and safety (, 152). Consequently, a reduced dosage of IL-2 could decelerate atherosclerosis by controlling T-cells. To sum up, specific T-cell treatment methods may hold promise for atherosclerosis linked to SLE, yet additional studies are required to confirm their effectiveness and safety.

4.7 Targeted B cell therapy

B-cell-directed therapies emerge as viable interventions for SLE-linked AS. BAFF serves as a crucial modulator of B-cell homeostasis and SLE pathogenesis (153). The BAFF-neutralizing monoclonal antibody belimumab—an approved SLE biologic—demonstrates dual therapeutic capacity by achieving disease activity control and renal protection in lupus nephritis (153). Its anti-atherogenic effects exhibit context-dependent effects contingent upon lipidomic profiles and B-cell functional states, underscoring the necessity for precision targeting strategies (154). Clinical data reveal belimumab’s concomitant HDL elevation and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score reduction, suggesting synergistic metabolic-immune benefits in AS mitigation (155). Complementary approaches employ CD20-directed agents like rituximab that mediate pathogenic B-cell depletion while preserving protective autoantibody pools, concurrently suppressing pathogenic T-cell cross-activation to impede AS progression (, 156). Notably, rituximab ameliorates dyslipidemia in refractory SLE cases and attenuates myocardial infarction risk through pleiotropic immunometabolic mechanisms (, 157). These findings position B-cell modulation as a strategic axis in SLE-related AS management, though future investigations must delineate molecular stratification biomarkers and establish dynamic monitoring protocols to optimize risk-adapted therapeutic strategies.

4.8 Potential therapies of targeting gut microbiota and metabolism in treating SLE-related atherosclerosis

Atherosclerosis is a significant cardiovascular complication in patients with SLE. Targeting gut microbiota and metabolic disorders has emerged as a novel approach to treat SLE-related atherosclerosis. Despite limited preclinical evidence, this approach holds significant promise for modulating both autoimmunity and vascular inflammation. Potential therapies include gene intervention, probiotic therapy, fecal microbiota transplantation, TMAO and tryptophan metabolism regulation, SCFA therapy and pharmacological or nutritional therapies. Relevant studies are listed in Supplementary Table 1.

4.8.1 Gene intervention

Gene intervention may improve gut microbiota dysbiosis and metabolic abnormalities to benefit atherosclerosis. NOD1/NOD2-deficient mice had less atherosclerosis than Ldlr-/- mice after a 12-week high-fat diet, due to gut microbiota changes, increased intestinal cholesterol and coprostanol levels correlating with more Eubacterium coprostanoligenes, and lower plasma lipid levels and reduced foam cell formation from upregulated Abca1 and Abcg1 in macrophages (158). PSRC1 deficiency in ApoE-/- mice accelerated atherosclerosis by boosting TMAO, increased TMA-producing bacteria and plasma betaine and TMAO levels. These mice also showed colonic inflammation linked to gut microbiota dysregulation and PSRC1 deficiency increased liver flavin monooxygenase 3 (FMO3) expression, while PSRC1 overexpression suppressed FMO3 (112). These results highlight gene intervention’s potential to modulate gut microbiota and metabolic pathways to combat atherosclerosis, though more clinical research is needed for human validation.

4.8.2 Probiotic therapy

A population study and in vivo experiments using ApoE-/- mice revealed that Faecalibacterium prausnitzii presence is associated with the lowest CAD incidence. Faecalibacterium prausnitzii reduces intestinal LPS synthesis, enhances mechanical and mucosal barriers, decreases plasma LPS levels, and alleviates atherosclerosis in ApoE-/- mice (110). A human study and in vivo experiments showed Bacteroides vulgatus and Bacteroides dorei abundance is reduced in CAD patients, while administering these bacteria alleviates atherosclerotic lesion formation in mice and reduces gut microbiota LPS production (159). Another study demonstrated that Roseburia intestinalis interacts with dietary plant polysaccharides to improve gut metabolism, reduce systemic inflammation, and significantly alleviate atherosclerosis. Intestinal butyrate administration can also reduce endotoxemia and atherosclerosis development (160). The research investigated a high-fat diet and interventions with LGG or telmisartan on atherosclerosis in ApoE-/- mice, finding both LGG and telmisartan significantly reduced atherosclerotic plaque size and improved various biomarkers (161). However, further clinical research is needed to validate these therapeutic effects in human patients.

4.8.3 Fecal microbiota transplantation

FMT may be an effective strategy for treating atherosclerosis by modulating the gut microbiota. One study showed that Z-Ligustilide significantly alleviates atherosclerosis in ApoE-/- mice by reconstructing gut microbiota and maintaining intestinal barrier integrity via cannabinoid receptor 2 activation. Fecal bacteria from Z-Ligustilide-treated mice induced similar beneficial effects, and 16S RNA gene sequencing revealed a significant increase in Rikenella abundance in both Z-Ligustilide-treated and FMT mice (162). Another study showed Empagliflozin alleviates atherosclerosis, increases fecal probiotics abundance, reduces inflammatory responses, and alters gut microbiota metabolism; FMT from empagliflozin-treated mice to control mice also reduced atherosclerosis and systemic inflammatory responses (163). Furthermore, research using a C1q/TNF-related protein 9 gene-deficient (CTRP9-KO) mouse model found transplanting gut microbiota from wild-type mice into CTRP9-KO mice alleviated the development of atherosclerosis (164). However, further clinical research is needed to validate the efficacy and safety of FMT in human patients.

4.8.4 TMAO regulation therapy

Targeting TMAO biosynthesis emerges as a novel therapeutic frontier for SLE-associated atherosclerosis. Pharmacological inhibition of TMA lyase by 3,3-dimethyl-1-butanol (DMB) in imiquimod-induced lupus models demonstrates multi-organ protection through TMAO suppression, including endothelial function restoration and macrophage foam cell formation inhibition independent of cholesterol modulation ().

Complementary studies reveal diverse TMAO modulation strategies: Puerarin exerts atheroprotection via Prevotella copri depletion and TMA precursor reduction, while berberine’s vitamin-mimetic metabolite dihydroberberine disrupts gut microbial TMA biosynthesis (165, 166). Dietary interventions further expand this paradigm – aged garlic oligosaccharides reshape gut ecology toward Akkermansia-dominant communities with concomitant TMAO reduction in hyperlipidemic ApoE-/- models, whereas hickory polyphenols attenuate atherosclerosis through hepatic FMO3 transcriptional downregulation in high-choline-fed C57BL/6J mice (167, 168). Further clinical trials are necessary to confirm the efficacy and safety of these interventions in human patients.

4.8.5 Tryptophan metabolism regulation therapy

Recent studies highlight tryptophan metabolism’s potential therapeutic role in atherosclerosis. A clinical trial and in vivo experiment in ApoE-/- mice revealed that IPA was significantly downregulated in CAD patients, correlating with atherosclerotic cardiovascular disease (ASCVD) risk and severity. Dietary IPA supplementation in ApoE-/- mice alleviated plaque development via the miR-142-5p/ABCA1 pathway by promoting cholesterol efflux. This study first uncovered the link between gut microbiota-derived tryptophan metabolites and ASCVD, providing a potential target (122). Another study showed that Aucubin improves atherosclerosis in ApoE-/- mice by modulating gut microbiota, particularly by increasing indole-3-acrylic acid (IAA). IAA alleviates atherosclerosis by activating the Aryl hydrocarbon receptor (AhR) and inhibiting the TGF-β/Smad pathway (169). Similarly, Indole-3-carbinol (I3C) inhibits atherosclerosis in ApoE-/- mice. I3C improves lipid profile, enhances gut microbiota diversity, and increases Verrucomicrobia abundance. Integrated analysis shows that 1-methyladenosine is a key modulator of I3C’s protective effect (170). These findings indicate that modulating tryptophan metabolism and gut microbiota could be promising therapeutic strategies for atherosclerosis, but more large-scale studies are needed to confirm their efficacy and safety in humans.

4.8.6 Short-chain fatty acids regulation therapy

Short-chain fatty acids (SCFAs) show potential in treating atherosclerosis. Propionate (PA) reduces intestinal cholesterol absorption and lowers plasma LDL cholesterol via immune mechanisms, increasing regulatory T cells and IL-10 while inhibiting Npc1l1 expression. Oral PA supplementation in humans significantly decreases cholesterol levels, offering a new therapeutic target (171). In ApoE-/- mice, Roseburia intestinalis interacts with dietary plant polysaccharides to improve gut metabolism and reduce atherosclerosis, revealing gut microbiota and diet interaction mechanisms (160). These studies suggest SCFAs’ role in combating atherosclerosis through gut microbiota and immune modulation, though human validation is still required.

4.8.7 Pharmacological or nutritional therapies

Recent studies have illuminated the potential of various treatments in improving atherosclerosis via gut microbiota modulation. One study found gut microbiota affects atherosclerosis development by regulating vascular microRNA-204 expression, which impacts vascular endothelial function by targeting Sirtuin1 (172). Bicyclol improves high-fat diet-induced atherosclerosis in ApoE-/- mice by restoring gut health and alleviating endothelial activation, macrophage infiltration, and cholesterol ester accumulation (173). Hydroxyurea effectively mitigates atherosclerosis in ApoE-/- mice by modulating gut microbiota and cholesterol metabolism, reducing plaque and liver lipid accumulation (174). Palmatine significantly mitigates atherosclerosis by modulating gut microbiota and phenylalanine metabolism, reshaping gut microbiota composition and reducing harmful bacteria abundance (175). Peanut Skin Extract significantly mitigates atherosclerosis in ApoE-/- mice by regulating lipid metabolism, exerting anti-inflammatory effects, and altering gut microbiota composition (176). Ginsenosides protect Ldlr-/- mice from atherosclerosis by enhancing bile salt hydrolase activity and protecting the intestinal barrier (177). ALW-II-41–27 significantly alleviates atherosclerosis in ApoE-/- mice by reshaping gut microbiota and modulating bile acid metabolism, reducing plaques and increasing collagen and smooth muscle cell content (178). Disulfiram reduces atherosclerosis in ApoE-/- mice by inhibiting GsdmD, inducing autophagy, and modulating gut microbiota (179). Dietary fiber also benefits SLE mice by modulating gut microbiota and improving vascular and renal health (180). These findings highlight the potential of targeting gut microbiota as a therapeutic strategy for atherosclerosis, with further human validation needed.

5 Future perspectives

SLE, a complex autoimmune disorder, increases the risk of atherosclerosis. Despite recent progress, challenges remain. This review connects SLE with atherosclerosis through immune imbalance, gut microbiota disturbances, and metabolic differences, and suggests future research and treatment strategies.

The paper revisits atherosclerosis risk factors in SLE, including both traditional cardiovascular risks and unique SLE pathophysiology. Recent studies highlight immune cell dysfunction, particularly macrophage metabolism imbalance and the role of LNGs and CD4+T-cells under type I interferon conditions, leading to mitochondrial damage and oxidative stress, which promote atherosclerosis. Lipid metabolism irregularities, disease activity also accelerate the condition.

Current therapies including statins, corticosteroids, immunosuppressants, antimalarials, and targeted molecular agents aim to modulate lipid profiles, inflammatory responses, immune activation, and gut microbiota composition to mitigate cardiovascular risks. Future investigations should prioritize uncovering novel atherogenic mechanisms in SLE, particularly immune-metabolic interactions in specialized cell populations.

Study limitations include predominant reliance on animal models and in vitro systems that may not accurately reflect human SLE pathophysiology. Disease heterogeneity necessitates rigorously designed clinical studies. Research priorities should focus on developing personalized therapies, elucidating immune cell contributions to vascular pathology, investigating gut microbiota-metabolism crosstalk, and identifying predictive biomarkers. The underexplored relationship between specific gut microbial species/metabolites and oxidative atherogenesis in SLE warrants particular attention, as this may reveal novel therapeutic targets and diagnostic tools.

Advances in SLE-related atherosclerosis research could inform cardiovascular management across autoimmune disorders. Multicenter clinical trials, interdisciplinary collaborations, and data-sharing platforms are critical for accelerating progress. Although challenges remain, emerging technologies offer optimism for developing precision therapies that improve SLE patients’ cardiovascular outcomes and overall quality of life. This synthesis enhances understanding of SLE-associated vascular pathogenesis and provides translational insights applicable to broader autoimmune research.

Statements

Author contributions

QRP: Writing – original draft, Writing – review & editing. XH: Writing – original draft, Writing – review & editing. CL: Writing – review & editing. QJP: Writing – review & editing. SH: Funding acquisition, Writing – review & editing.

Funding

The author(s) declare that financial support was received for the research and/or publication of this article. This study was supported by the Construction of Zhanjiang Vascular remodeling and arrhythmia Medical Engineering Research Center (no. 2020A06003) (SH).

Acknowledgments

Figures were created using BioRender (BioRender, Canada; BioRender.com; Agreement numbers: HU284B7TAI; KH284B7UXZ; IL284B7WHC; HD284B7ZJG; ET284B82K5).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2025.1492726/full#supplementary-material

Glossary

  • apoA1

    Apolipoprotein A1

  • LDGs

    Low-Density Granulocytes

  • AS

    atherosclerosis

  • LOX-1

    Lectin-like oxidized low-density lipoprotein receptor-1

  • ASCVD

    atherosclerotic cardiovascular disease

  • LPS

    Lipopolysaccharide

  • BAFF

    B-cell-activating factor

  • MAPKs

    Mitogen-activated protein kinases

  • CACs

    circumferential artery cells

  • MDA

    malondialdehyde

  • CAD

    coronary artery disease

  • MMF

    Mycophenolate mofetil

  • cGAS-STING

    cyclic GMP-AMP synthase - stimulator of interferon genes pathway

  • MMP

    Matrix Metalloproteinase

  • CPA

    cyclophosphamide

  • MPO

    Myeloperoxidase

  • CVDs

    cardiovascular diseases

  • MyD88

    myeloid differentiation factor 88

  • DMB

    3,3-dimethyl-1-butanol

  • NETs

    Neutrophil Extracellular Traps

  • DNase I

    Deoxyribonuclease I

  • NF-κB

    Nuclear Factor Kappa B

  • ECM

    extracellular matrix

  • NOX

    NADPH Oxidase

  • EPCs

    endothelial progenitor cells

  • NOS

    Nitric Oxide Synthase

  • FMO3

    flavin monooxygenase 3

  • Ox mtDNA

    Oxidized Mitochondrial DNA

  • FMT

    Fecal Microbiota Transplantation

  • oxLDL

    Oxidized Low-Density Lipoprotein

  • HCQ

    hydroxychloroquine

  • PAD

    Peptidylarginine Deiminase

  • HDL

    High-Density Lipoprotein

  • PC

    Phosphatidylcholine

  • HFD

    high-fat diet

  • pDCs

    Plasmacytoid Dendritic Cells

  • HGF

    hepatocyte growth factor

  • PD-L1

    programmed death ligand 1

  • HMGB1

    High Mobility Group Box 1

  • PKM2

    pyruvate kinase M2

  • IAA

    indole-3-acrylic acid

  • PON1

    Paraoxonase 1

  • I3C

    Indole-3-carbinol

  • ROS

    Reactive Oxygen Species

  • ICAM-1

    Intercellular Adhesion Molecule-1

  • SCFAs

    Short-Chain Fatty Acids

  • ICs

    immune complexes

  • SLE

    systemic lupus erythematosus

  • IDO1

    indoleamine 2,3-dioxygenase 1

  • SR-A1

    scavenger receptor A1

  • IFN-I

    Type I interferons

  • Tang cells

    CD3+CD31+CXCR4+ angiogenic T-cells

  • TYK2/JAK1

    IFNAR-mediated JAK kinase

  • Tfh

    Follicular helper T-cells

  • iNKT

    Invariant Natural Killer T-cells

  • Th1

    CXCR3+ T helper 1 cells

  • IPA

    indole-3-propionic acid

  • TJPs

    Tight Junction Proteins

  • IRF

    Interferon regulatory factor

  • TLR

    Toll-like receptors

  • ISGs

    interferon-stimulated genes

  • TMA

    Trimethylamine

  • ISRE

    interferon-stimulated response element

  • TMAO

    Trimethylamine-N-Oxide

  • JAKi

    Janus kinase inhibitors

  • VCAM-1

    Vascular Cell Adhesion Molecule-1

  • LBP

    Lipopolysaccharide Binding Protein

  • VEGF

    vascular endothelial growth factor

  • LDL

    low-density lipoprotein

  • VSMC

    vascular smooth muscle cell.

References

  • 1

    OliveiraCBKaplanMJ. Cardiovascular disease risk and pathogenesis in systemic lupus erythematosus. Semin Immunopathol. (2022) 44:309–24. doi: 10.1007/s00281-022-00922-y

  • 2

    JinLShiXYangJZhaoYXueLXuLet al. Gut microbes in cardiovascular diseases and their potential therapeutic applications. Protein Cell. (2021) 12:346–59. doi: 10.1007/s13238-020-00785-9

  • 3

    ChenCKhismatullinDB. Oxidized low-density lipoprotein contributes to atherogenesis via co-activation of macrophages and mast cells. PLoS One. (2015) 10:e0123088. doi: 10.1371/journal.pone.0123088

  • 4

    Garcia-RomoGSCaielliSVegaBConnollyJAllantazFXuZet al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med. (2011) 3:73ra20. doi: 10.1126/scitranslmed.3001201

  • 5

    TeixeiraVTamLS. Novel insights in systemic lupus erythematosus and atherosclerosis. Front Med (Lausanne). (2017) 4:262. doi: 10.3389/fmed.2017.00262

  • 6

    SchwartzDMBurmaAMKitakuleMMLuoYMehtaNN. T cells in autoimmunity-associated cardiovascular diseases. Front Immunol. (2020) 11:588776. doi: 10.3389/fimmu.2020.588776

  • 7

    SrikakulapuPMcNamaraCA. B cells and atherosclerosis. Am J Physiol Heart Circ Physiol. (2017) 312:H1060–7. doi: 10.1152/ajpheart.00859.2016

  • 8

    da SilvaFFLevyRAde CarvalhoJF. Cardiovascular risk factors in the antiphospholipid syndrome. J Immunol Res. (2014) 2014:621270. doi: 10.1155/2014/621270

  • 9

    BrandsmaEKloosterhuisNJKosterMDekkerDCGijbelsMJJvan der VeldenSet al. A proinflammatory gut microbiota increases systemic inflammation and accelerates atherosclerosis. Circ Res. (2019) 124:94–100. doi: 10.1161/CIRCRESAHA.118.313234

  • 10

    ShiGLinYWuYZhouJCaoLChenJet al. Bacteroides fragilis supplementation deteriorated metabolic dysfunction, inflammation, and aorta atherosclerosis by inducing gut microbiota dysbiosis in animal model. Nutrients. (2022) 14:2199. doi: 10.3390/nu14112199

  • 11

    KoethRALam-GalvezBRKirsopJWangZLevisonBSGuXet al. l-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans. J Clin Invest. (2019) 129:373–87. doi: 10.1172/JCI94601

  • 12

    PanQGuoFHuangYLiAChenSChenJet al. Gut microbiota dysbiosis in systemic lupus erythematosus: novel insights into mechanisms and promising therapeutic strategies. Front Immunol. (2021) 12:799788. doi: 10.3389/fimmu.2021.799788

  • 13

    ChenBDJiaXMXuJYZhaoLDJiJYWuBXet al. An autoimmunogenic and proinflammatory profile defined by the gut microbiota of patients with untreated systemic lupus erythematosus. Arthritis Rheumatol. (2021) 73:232–43. doi: 10.1002/art.41511

  • 14

    MorandEPikeMMerrillJTvan VollenhovenRWerthVPHobarCet al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: A phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. (2023) 75:242–52. doi: 10.1002/art.42391

  • 15

    HeJZhangRShaoMZhaoXMiaoMChenJet al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. (2020) 79:141–9. doi: 10.1136/annrheumdis-2019-215396

  • 16

    Pego-ReigosaJMLuTYFontanilloMFdel Campo-PerezVRahmanAIsenbergDA. Long-term improvement of lipid profile in patients with refractory systemic lupus erythematosus treated with B-cell depletion therapy: a retrospective observational study. Rheumatol (Oxford). (2010) 49:691–6. doi: 10.1093/rheumatology/kep446

  • 17

    Gonzalez-CorreaCMoleonJMinanoSVisitacionNRobles-VeraIGomez-GuzmanMet al. Trimethylamine N-oxide promotes autoimmunity and a loss of vascular function in toll-like receptor 7-driven lupus mice. Antioxidants (Basel). (2021) 11:84. doi: 10.3390/antiox11010084

  • 18

    SircanaMCErreGLCastagnaFManettiR. Crosstalk between inflammation and atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus: is there a common basis? Life (Basel). (2024) 14:716. doi: 10.3390/life14060716

  • 19

    MehtaNNTeagueHLSwindellWRBaumerYWardNLXingXet al. IFN-gamma and TNF-alpha synergism may provide a link between psoriasis and inflammatory atherogenesis. Sci Rep. (2017) 7:13831. doi: 10.1038/s41598-017-14365-1

  • 20

    KimSYYuMMorinEEKangJKaplanMJSchwendemanA. High-density lipoprotein in lupus: disease biomarkers and potential therapeutic strategy. Arthritis Rheumatol. (2020) 72:20–30. doi: 10.1002/art.41059

  • 21

    AmblerWGKaplanMJ. Vascular damage in systemic lupus erythematosus. Nat Rev Nephrol. (2024) 20:251–65. doi: 10.1038/s41581-023-00797-8

  • 22

    PerlA. Oxidative stress in the pathology and treatment of systemic lupus erythematosus. Nat Rev Rheumatol. (2013) 9:674–86. doi: 10.1038/nrrheum.2013.147

  • 23

    Lopez-PedreraCBarbarrojaNJimenez-GomezYCollantes-EstevezEAguirreMACuadradoMJ. Oxidative stress in the pathogenesis of atherothrombosis associated with anti-phospholipid syndrome and systemic lupus erythematosus: new therapeutic approaches. Rheumatol (Oxford). (2016) 55:2096–108. doi: 10.1093/rheumatology/kew054

  • 24

    BorenJChapmanMJKraussRMPackardCJBentzonJFBinderCJet al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. (2020) 41:2313–30. doi: 10.1093/eurheartj/ehz962

  • 25

    Martin-FuentesPCiveiraFRecaldeDGarcia-OtinALJarautaEMarzoIet al. Individual variation of scavenger receptor expression in human macrophages with oxidized low-density lipoprotein is associated with a differential inflammatory response. J Immunol. (2007) 179:3242–8. doi: 10.4049/jimmunol.179.5.3242

  • 26

    MushenkovaNVBezsonovEEOrekhovaVAPopkovaTVStarodubovaAVOrekhovAN. Recognition of oxidized lipids by macrophages and its role in atherosclerosis development. Biomedicines. (2021) 9:915. doi: 10.3390/biomedicines9080915

  • 27

    LiJFuQCuiHQuBPanWShenNet al. Interferon-alpha priming promotes lipid uptake and macrophage-derived foam cell formation: a novel link between interferon-alpha and atherosclerosis in lupus. Arthritis Rheum. (2011) 63:492–502. doi: 10.1002/art.30165

  • 28

    RobinsonGAWilkinsonMGLWincupC. The role of immunometabolism in the pathogenesis of systemic lupus erythematosus. Front Immunol. (2021) 12:806560. doi: 10.3389/fimmu.2021.806560

  • 29

    BarrettTJ. Macrophages in atherosclerosis regression. Arterioscler Thromb Vasc Biol. (2020) 40:20–33. doi: 10.1161/ATVBAHA.119.312802

  • 30

    WangYSuWLiYYuanJYaoMSuXet al. Analyzing the pathogenesis of systemic lupus erythematosus complicated by atherosclerosis using transcriptome data. Front Immunol. (2022) 13:935545. doi: 10.3389/fimmu.2022.935545

  • 31

    AppletonBDMajorAS. The latest in systemic lupus erythematosus-accelerated atherosclerosis: related mechanisms inform assessment and therapy. Curr Opin Rheumatol. (2021) 33:211–8. doi: 10.1097/BOR.0000000000000773

  • 32

    BennettMRSinhaSOwensGK. Vascular smooth muscle cells in atherosclerosis. Circ Res. (2016) 118:692–702. doi: 10.1161/CIRCRESAHA.115.306361

  • 33

    QuillardTAraujoHAFranckGShvartzESukhovaGLibbyP. TLR2 and neutrophils potentiate endothelial stress, apoptosis and detachment: implications for superficial erosion. Eur Heart J. (2015) 36:1394–404. doi: 10.1093/eurheartj/ehv044

  • 34

    McNabFMayer-BarberKSherAWackAO’GarraA. Type I interferons in infectious disease. Nat Rev Immunol. (2015) 15:87–103. doi: 10.1038/nri3787

  • 35

    PostalMVivaldoJFFernandez-RuizRParedesJLAppenzellerSNiewoldTB. Type I interferon in the pathogenesis of systemic lupus erythematosus. Curr Opin Immunol. (2020) 67:87–94. doi: 10.1016/j.coi.2020.10.014

  • 36

    O’NeillLA. Immunology. Sensing the dark side of DNA. Science. (2013) 339:763–4. doi: 10.1126/science.1234724

  • 37

    DingXXiangWHeX. IFN-I mediates dysfunction of endothelial progenitor cells in atherosclerosis of systemic lupus erythematosus. Front Immunol. (2020) 11:581385. doi: 10.3389/fimmu.2020.581385

  • 38

    AhadASmitaSMishraGPBiswasVKSenKGuptaBet al. NCoR1 fine-tunes type-I IFN response in cDC1 dendritic cells by directly regulating Myd88-IRF7 axis under TLR9. Eur J Immunol. (2020) 50:1959–75. doi: 10.1002/eji.202048566

  • 39

    DennyMFThackerSMehtaHSomersECDodickTBarratFJet al. Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood. (2007) 110:2907–15. doi: 10.1182/blood-2007-05-089086

  • 40

    ThackerSGBerthierCCMattinzoliDRastaldiMPKretzlerMKaplanMJ. The detrimental effects of IFN-alpha on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. J Immunol. (2010) 185:4457–69. doi: 10.4049/jimmunol.1001782

  • 41

    RajagopalanSSomersECBrookRDKehrerCPfenningerDLewisEet al. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood. (2004) 103:3677–83. doi: 10.1182/blood-2003-09-3198

  • 42

    ThackerSGZhaoWSmithCKLuoWWangHVivekanandan-GiriAet al. Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosis. Arthritis Rheum. (2012) 64:2975–85. doi: 10.1002/art.34504

  • 43

    KahlenbergJMThackerSGBerthierCCCohenCDKretzlerMKaplanMJ. Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus. J Immunol. (2011) 187:6143–56. doi: 10.4049/jimmunol.1101284

  • 44

    AzzouzDKhanMAPalaniyarN. ROS induces NETosis by oxidizing DNA and initiating DNA repair. Cell Death Discov. (2021) 7:113. doi: 10.1038/s41420-021-00491-3

  • 45

    RahmanSSagarDHannaRNLightfootYLMistryPSmithCKet al. Low-density granulocytes activate T cells and demonstrate a non-suppressive role in systemic lupus erythematosus. Ann Rheum Dis. (2019) 78:957–66. doi: 10.1136/annrheumdis-2018-214620

  • 46

    WangHLiTChenSGuYYeS. Neutrophil extracellular trap mitochondrial DNA and its autoantibody in systemic lupus erythematosus and a proof-of-concept trial of metformin. Arthritis Rheumatol. (2015) 67:3190–200. doi: 10.1002/art.39296

  • 47

    WigerbladGKaplanMJ. Neutrophil extracellular traps in systemic autoimmune and autoinflammatory diseases. Nat Rev Immunol. (2023) 23:274–88. doi: 10.1038/s41577-022-00787-0

  • 48

    Carmona-RiveraCZhaoWYalavarthiSKaplanMJ. Neutrophil extracellular traps induce endothelial dysfunction in systemic lupus erythematosus through the activation of matrix metalloproteinase-2. Ann Rheum Dis. (2015) 74:1417–24. doi: 10.1136/annrheumdis-2013-204837

  • 49

    BlancoLPWangXCarlucciPMTorres-RuizJJRomo-TenaJSunHWet al. RNA externalized by neutrophil extracellular traps promotes inflammatory pathways in endothelial cells. Arthritis Rheumatol. (2021) 73:2282–92. doi: 10.1002/art.41796

  • 50

    KahlenbergJMKaplanMJ. Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease. J Immunol. (2013) 191:4895–901. doi: 10.4049/jimmunol.1302005

  • 51

    LoodCBlancoLPPurmalekMMCarmona-RiveraCDe RavinSSSmithCKet al. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. Nat Med. (2016) 22:146–53. doi: 10.1038/nm.4027

  • 52

    CaielliSAthaleSDomicBMuratEChandraMBanchereauRet al. Oxidized mitochondrial nucleoids released by neutrophils drive type I interferon production in human lupus. J Exp Med. (2016) 213:697–713. doi: 10.1084/jem.20151876

  • 53

    HakkimAFurnrohrBGAmannKLaubeBAbedUABrinkmannVet al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A. (2010) 107:9813–8. doi: 10.1073/pnas.0909927107

  • 54

    MagnaMPisetskyDS. The role of HMGB1 in the pathogenesis of inflammatory and autoimmune diseases. Mol Med. (2014) 20:138–46. doi: 10.2119/molmed.2013.00164

  • 55

    KahlenbergJMCarmona-RiveraCSmithCKKaplanMJ. Neutrophil extracellular trap-associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages. J Immunol. (2013) 190:1217–26. doi: 10.4049/jimmunol.1202388

  • 56

    SmithCKVivekanandan-GiriATangCKnightJSMathewAPadillaRLet al. Neutrophil extracellular trap-derived enzymes oxidize high-density lipoprotein: an additional proatherogenic mechanism in systemic lupus erythematosus. Arthritis Rheumatol. (2014) 66:2532–44. doi: 10.1002/art.38703

  • 57

    ContiFSpinelliFRAlessandriCPacelliMCeccarelliFMarocchiEet al. Subclinical atherosclerosis in systemic lupus erythematosus and antiphospholipid syndrome: focus on beta2GPI-specific T cell response. Arterioscler Thromb Vasc Biol. (2014) 34:661–8. doi: 10.1161/ATVBAHA.113.302680

  • 58

    ClementMCharlesNEscoubetBGuedjKChauveheidMPCaligiuriGet al. CD4+CXCR3+ T cells and plasmacytoid dendritic cells drive accelerated atherosclerosis associated with systemic lupus erythematosus. J Autoimmun. (2015) 63:59–67. doi: 10.1016/j.jaut.2015.07.001

  • 59

    BaragettiARamirezGAMagnoniMGarlaschelliKGrigoreLBerteottiMet al. Disease trends over time and CD4(+)CCR5(+) T-cells expansion predict carotid atherosclerosis development in patients with systemic lupus erythematosus. Nutr Metab Cardiovasc Dis. (2018) 28:53–63. doi: 10.1016/j.numecd.2017.09.001

  • 60

    QinSRottmanJBMyersPKassamNWeinblattMLoetscherMet al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest. (1998) 101:746–54. doi: 10.1172/JCI1422

  • 61

    LiJMcArdleSGholamiAKimuraTWolfDGerhardtTet al. CCR5+T-bet+FoxP3+ Effector CD4 T cells drive atherosclerosis. Circ Res. (2016) 118:1540–52. doi: 10.1161/CIRCRESAHA.116.308648

  • 62

    LiWElshikhaASCornabyCTengXAbboudGBrownJet al. T cells expressing the lupus susceptibility allele Pbx1d enhance autoimmunity and atherosclerosis in dyslipidemic mice. JCI Insight. (2020) 5:e138274. doi: 10.1172/jci.insight.138274

  • 63

    GaddisDEPadgettLEWuRMcSkimmingCRominesVTaylorAMet al. Apolipoprotein AI prevents regulatory to follicular helper T cell switching during atherosclerosis. Nat Commun. (2018) 9:1095. doi: 10.1038/s41467-018-03493-5

  • 64

    TayCLiuYHKanellakisPKalliesALiYCaoAet al. Follicular B cells promote atherosclerosis via T cell-mediated differentiation into plasma cells and secreting pathogenic immunoglobulin G. Arterioscler Thromb Vasc Biol. (2018) 38:e71–84. doi: 10.1161/ATVBAHA.117.310678

  • 65

    Ghamar TalepoorAKhosropanahSDoroudchiM. Functional subsets of circulating follicular helper T cells in patients with atherosclerosis. Physiol Rep. (2020) 8:e14637. doi: 10.14814/phy2.14637

  • 66

    ZhuMMoHLiDLuoXZhangL. Th17/Treg imbalance induced by increased incidence of atherosclerosis in patients with systemic lupus erythematosus (SLE). Clin Rheumatol. (2013) 32:1045–52. doi: 10.1007/s10067-013-2237-z

  • 67

    WilhelmAJRhoadsJPWadeNSMajorAS. Dysregulated CD4+ T cells from SLE-susceptible mice are sufficient to accelerate atherosclerosis in LDLr-/- mice. Ann Rheum Dis. (2015) 74:778–85. doi: 10.1136/annrheumdis-2013-203759

  • 68

    TellidesGTerebDAKirkiles-SmithNCKimRWWilsonJHSchechnerJSet al. Interferon-gamma elicits arteriosclerosis in the absence of leukocytes. Nature. (2000) 403:207–11. doi: 10.1038/35003221

  • 69

    PerezRKGordonMGSubramaniamMKimMCHartoularosGCTargSet al. Single-cell RNA-seq reveals cell type-specific molecular and genetic associations to lupus. Science. (2022) 376:eabf1970. doi: 10.1126/science.abf1970

  • 70

    HurJYangHMYoonCHLeeCSParkKWKimJHet al. Identification of a novel role of T cells in postnatal vasculogenesis: characterization of endothelial progenitor cell colonies. Circulation. (2007) 116:1671–82. doi: 10.1161/CIRCULATIONAHA.107.694778

  • 71

    MiaoJQiuFLiTZhaoPZhangKLvMet al. Circulating angiogenic T cells and their subpopulations in patients with systemic lupus erythematosus. Mediators Inflammation. (2016) 2016:2842143. doi: 10.1155/2016/2842143

  • 72

    LopezPRodriguez-CarrioJMartinez-ZapicoACaminal-MonteroLSuarezA. Senescent profile of angiogenic T cells from systemic lupus erythematosus patients. J Leukoc Biol. (2016) 99:405–12. doi: 10.1189/jlb.5HI0215-042R

  • 73

    BortoluzziAChighizolaCBFrediMRaschiEBodioCPriviteraDet al. The IMMENSE study: the interplay between iMMune and ENdothelial cells in mediating cardiovascular risk in systemic lupus erythematosus. Front Immunol. (2020) 11:572876. doi: 10.3389/fimmu.2020.572876

  • 74

    ChoYNKeeSJLeeSJSeoSRKimTJLeeSSet al. Numerical and functional deficiencies of natural killer T cells in systemic lupus erythematosus: their deficiency related to disease activity. Rheumatol (Oxford). (2011) 50:1054–63. doi: 10.1093/rheumatology/keq457

  • 75

    BondarenkoSCatapanoALNorataGD. The CD1d-natural killer T cell axis in atherosclerosis. J Innate Immun. (2014) 6:3–12. doi: 10.1159/000351034

  • 76

    LuSDengJLiuHLiuBYangJMiaoYet al. PKM2-dependent metabolic reprogramming in CD4(+) T cells is crucial for hyperhomocysteinemia-accelerated atherosclerosis. J Mol Med (Berl). (2018) 96:585–600. doi: 10.1007/s00109-018-1645-6

  • 77

    YennemadiASKeaneJLeischingG. Mitochondrial bioenergetic changes in systemic lupus erythematosus immune cell subsets: Contributions to pathogenesis and clinical applications. Lupus. (2023) 32:603–11. doi: 10.1177/09612033231164635

  • 78

    YinYChoiSCXuZPerryDJSeayHCrokerBPet al. Normalization of CD4+ T cell metabolism reverses lupus. Sci Transl Med. (2015) 7:274ra18. doi: 10.1126/scitranslmed.aaa0835

  • 79

    CrocaSBassettPChambersSDavariMAlberKFLeachOet al. IgG anti-apolipoprotein A-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study. Arthritis Res Ther. (2015) 17:26. doi: 10.1186/s13075-015-0539-z

  • 80

    LopezPRodriguez-CarrioJMartinez-ZapicoAPerez-AlvarezAILopez-MejiasRBenaventeLet al. Serum levels of anti-PON1 and anti-HDL antibodies as potential biomarkers of premature atherosclerosis in systemic lupus erythematosus. Thromb Haemost. (2017) 117:2194–206. doi: 10.1160/TH17-03-0221

  • 81

    GronwallCReynoldsHKimJKBuyonJGoldbergJDClancyRMet al. Relation of carotid plaque with natural IgM antibodies in patients with systemic lupus erythematosus. Clin Immunol. (2014) 153:1–7. doi: 10.1016/j.clim.2014.03.017

  • 82

    AnaniaCGustafssonTHuaXSuJVikstromMde FaireUet al. Increased prevalence of vulnerable atherosclerotic plaques and low levels of natural IgM antibodies against phosphorylcholine in patients with systemic lupus erythematosus. Arthritis Res Ther. (2010) 12:R214. doi: 10.1186/ar3193

  • 83

    GronwallCAkhterEOhCBurlingameRWPetriMSilvermanGJ. IgM autoantibodies to distinct apoptosis-associated antigens correlate with protection from cardiovascular events and renal disease in patients with SLE. Clin Immunol. (2012) 142:390–8. doi: 10.1016/j.clim.2012.01.002

  • 84

    RahmanMSingSGolabkeshZFiskesundRGustafssonTJogestrandTet al. IgM antibodies against malondialdehyde and phosphorylcholine are together strong protection markers for atherosclerosis in systemic lupus erythematosus: Regulation and underlying mechanisms. Clin Immunol. (2016) 166-167:27–37. doi: 10.1016/j.clim.2016.04.007

  • 85

    SuJHuaXConchaHSvenungssonECederholmAFrostegardJ. Natural antibodies against phosphorylcholine as potential protective factors in SLE. Rheumatol (Oxford). (2008) 47:1144–50. doi: 10.1093/rheumatology/ken120

  • 86

    BraunNWadeNSWakelandEKMajorAS. Accelerated atherosclerosis is independent of feeding high fat diet in systemic lupus erythematosus-susceptible LDLr(-/-) mice. Lupus. (2008) 17:1070–8. doi: 10.1177/0961203308093551

  • 87

    StanicAKSteinCMMorganACFazioSLintonMFWakelandEKet al. Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosus. Proc Natl Acad Sci U S A. (2006) 103:7018–23. doi: 10.1073/pnas.0602311103

  • 88

    KurienBTFesmireJAndersonCJScofieldRH. Anti-ro and concomitant anti-la autoantibodies strongly associated with anti-oxLDL or anti-phospholipid antibody in systemic lupus erythematosus. J Clin Rheumatol. (2016) 22:418–25. doi: 10.1097/RHU.0000000000000429

  • 89

    ZhangXXieYZhouHXuYLiuJXieHet al. Involvement of TLR4 in oxidized LDL/beta2GPI/anti-beta2GPI-induced transformation of macrophages to foam cells. J Atheroscler Thromb. (2014) 21:1140–51. doi: 10.5551/jat.24372

  • 90

    TheodorouENezosAAntypaEIoakeimidisDKoutsilierisMTektonidouMet al. B-cell activating factor and related genetic variants in lupus related atherosclerosis. J Autoimmun. (2018) 92:87–92. doi: 10.1016/j.jaut.2018.05.002

  • 91

    NguyenTTBaumgarthN. Natural igM and the development of B cell-mediated autoimmune diseases. Crit Rev Immunol. (2016) 36:163–77. doi: 10.1615/CritRevImmunol.2016018175

  • 92

    EnghardPHumrichJYChuVTGrussieEHiepeFBurmesterGRet al. Class switching and consecutive loss of dsDNA-reactive B1a B cells from the peritoneal cavity during murine lupus development. Eur J Immunol. (2010) 40:1809–18. doi: 10.1002/eji.200940050

  • 93

    WitherJERoyVBrennanLA. Activated B cells express increased levels of costimulatory molecules in young autoimmune NZB and (NZB x NZW)F(1) mice. Clin Immunol. (2000) 94:51–63. doi: 10.1006/clim.1999.4806

  • 94

    MalkielSBarlevANAtisha-FregosoYSuurmondJDiamondB. Plasma cell differentiation pathways in systemic lupus erythematosus. Front Immunol. (2018) 9:427. doi: 10.3389/fimmu.2018.00427

  • 95

    DoringYMantheyHDDrechslerMLievensDMegensRTSoehnleinOet al. Auto-antigenic protein-DNA complexes stimulate plasmacytoid dendritic cells to promote atherosclerosis. Circulation. (2012) 125:1673–83. doi: 10.1161/CIRCULATIONAHA.111.046755

  • 96

    Patino-TrivesAMPerez-SanchezCPerez-SanchezLLuque-TevarMAbalos-AguileraMCAlcaide-RuggieroLet al. Anti-dsDNA antibodies increase the cardiovascular risk in systemic lupus erythematosus promoting a distinctive immune and vascular activation. Arterioscler Thromb Vasc Biol. (2021) 41:2417–30. doi: 10.1161/ATVBAHA.121.315928

  • 97

    CieslikPSemik-GrabarczykEHrycekAHoleckiM. The impact of anti-endothelial cell antibodies (AECAs) on the development of blood vessel damage in patients with systemic lupus erythematosus: the preliminary study. Rheumatol Int. (2022) 42:791–801. doi: 10.1007/s00296-022-05104-5

  • 98

    KondoATakahashiKMizunoTKatoAHiranoDYamamotoNet al. The level of igA antibodies to endothelial cells correlates with histological evidence of disease activity in patients with lupus nephritis. PLoS One. (2016) 11:e0163085. doi: 10.1371/journal.pone.0163085

  • 99

    Perez-SanchezCBarbarrojaNMessineoSRuiz-LimonPRodriguez-ArizaAJimenez-GomezYet al. Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus. Ann Rheum Dis. (2015) 74:1441–9. doi: 10.1136/annrheumdis-2013-204600

  • 100

    de FaireUFrostegardJ. Natural antibodies against phosphorylcholine in cardiovascular disease. Ann N Y Acad Sci. (2009) 1173:292–300. doi: 10.1111/j.1749-6632.2009.04748.x

  • 101

    SvenungssonEEngelbertsenDWigrenMGustafssonJTGunnarssonIElvinKet al. Decreased levels of autoantibodies against apolipoprotein B-100 antigens are associated with cardiovascular disease in systemic lupus erythematosus. Clin Exp Immunol. (2015) 181:417–26. doi: 10.1111/cei.12651

  • 102

    HoMMManughian-PeterASpiviaWRTaylorAFraserDA. Macrophage molecular signaling and inflammatory responses during ingestion of atherogenic lipoproteins are modulated by complement protein C1q. Atherosclerosis. (2016) 253:38–46. doi: 10.1016/j.atherosclerosis.2016.08.019

  • 103

    SunJLundstromSLZhangBZubarevRASteuerJGillgrenPet al. IgM antibodies against phosphorylcholine promote polarization of T regulatory cells from patients with atherosclerotic plaques, systemic lupus erythematosus and healthy donors. Atherosclerosis. (2018) 268:36–48. doi: 10.1016/j.atherosclerosis.2017.11.010

  • 104

    LourdudossCAjeganovaSFrostegardJ. Association between dietary and metabolic factors and IgM antibodies to phosphorylcholine and malondialdehyde in patients with systemic lupus erythematosus and population-based matched controls. Clin Exp Rheumatol. (2018) 36:428–33.

  • 105

    Cabana-PuigXLuRGengSMichaelisJSOakesVArmstrongCet al. CX(3)CR1 modulates SLE-associated glomerulonephritis and cardiovascular disease in MRL/lpr mice. Inflammation Res. (2023) 72:1083–97. doi: 10.1007/s00011-023-01731-1

  • 106

    Sanchez-RodriguezEEgea-ZorrillaAPlaza-DiazJAragon-VelaJMunoz-QuezadaSTercedor-SanchezLet al. The gut microbiota and its implication in the development of atherosclerosis and related cardiovascular diseases. Nutrients. (2020) 12:605. doi: 10.3390/nu12030605

  • 107

    TuomistoSHuhtalaHMartiskainenMGoebelerSLehtimakiTKarhunenPJ. Age-dependent association of gut bacteria with coronary atherosclerosis: Tampere Sudden Death Study. PLoS One. (2019) 14:e0221345. doi: 10.1371/journal.pone.0221345

  • 108

    ZhangKQinXQiuJSunTQuKDinAUet al. Desulfovibrio desulfuricans aggravates atherosclerosis by enhancing intestinal permeability and endothelial TLR4/NF-kappaB pathway in Apoe (-/-) mice. Genes Dis. (2023) 10:239–53. doi: 10.1016/j.gendis.2021.09.007

  • 109

    ShenXLiLSunZZangGZhangLShaoCet al. Gut microbiota and atherosclerosis-focusing on the plaque stability. Front Cardiovasc Med. (2021) 8:668532. doi: 10.3389/fcvm.2021.668532

  • 110

    YangHTJiangZHYangYWuTTZhengYYMaYTet al. Faecalibacterium prausnitzii as a potential Antiatherosclerotic microbe. Cell Commun Signal. (2024) 22:54. doi: 10.1186/s12964-023-01464-y

  • 111

    ParkSKimIHanSJKwonSMinEJChoWet al. Oral Porphyromonas gingivalis infection affects intestinal microbiota and promotes atherosclerosis. J Clin Periodontol. (2023) 50:1553–67. doi: 10.1111/jcpe.13864

  • 112

    LuoTGuoZLiuDGuoZWuQLiQet al. Deficiency of PSRC1 accelerates atherosclerosis by increasing TMAO production via manipulating gut microbiota and flavin monooxygenase 3. Gut Microbes. (2022) 14:2077602. doi: 10.1080/19490976.2022.2077602

  • 113

    SeldinMMMengYQiHZhuWWangZHazenSLet al. Trimethylamine N-oxide promotes vascular inflammation through signaling of mitogen-activated protein kinase and nuclear factor-kappaB. J Am Heart Assoc. (2016) 5:e002767. doi: 10.1161/JAHA.115.002767

  • 114

    ChenMLZhuXHRanLLangHDYiLMiMT. Trimethylamine-N-oxide induces vascular inflammation by activating the NLRP3 inflammasome through the SIRT3-SOD2-mtROS signaling pathway. J Am Heart Assoc. (2017) 6:e006347. doi: 10.1161/JAHA.117.006347

  • 115

    GengJYangCWangBZhangXHuTGuYet al. Trimethylamine N-oxide promotes atherosclerosis via CD36-dependent MAPK/JNK pathway. BioMed Pharmacother. (2018) 97:941–7. doi: 10.1016/j.biopha.2017.11.016

  • 116

    DingLChangMGuoYZhangLXueCYanagitaTet al. Trimethylamine-N-oxide (TMAO)-induced atherosclerosis is associated with bile acid metabolism. Lipids Health Dis. (2018) 17:286. doi: 10.1186/s12944-018-0939-6

  • 117

    CaiYYHuangFQLaoXLuYGaoXAlolgaRNet al. Integrated metagenomics identifies a crucial role for trimethylamine-producing Lachnoclostridium in promoting atherosclerosis. NPJ Biofilms Microbiomes. (2022) 8:11. doi: 10.1038/s41522-022-00273-4

  • 118

    ZhuWGregoryJCOrgEBuffaJAGuptaNWangZet al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell. (2016) 165:111–24. doi: 10.1016/j.cell.2016.02.011

  • 119

    LiYLiangLDengXZhongL. Lipidomic and metabolomic profiling reveals novel candidate biomarkers in active systemic lupus erythematosus. Int J Clin Exp Pathol. (2019) 12:857–66.

  • 120

    MetghalchiSPonnuswamyPSimonTHaddadYLauransLClementMet al. Indoleamine 2,3-dioxygenase fine-tunes immune homeostasis in atherosclerosis and colitis through repression of interleukin-10 production. Cell Metab. (2015) 22:460–71. doi: 10.1016/j.cmet.2015.07.004

  • 121

    LauransLVenteclefNHaddadYChajadineMAlzaidFMetghalchiSet al. Genetic deficiency of indoleamine 2,3-dioxygenase promotes gut microbiota-mediated metabolic health. Nat Med. (2018) 24:1113–20. doi: 10.1038/s41591-018-0060-4

  • 122

    XueHChenXYuCDengYZhangYChenSet al. Gut microbially produced indole-3-propionic acid inhibits atherosclerosis by promoting reverse cholesterol transport and its deficiency is causally related to atherosclerotic cardiovascular disease. Circ Res. (2022) 131:404–20. doi: 10.1161/CIRCRESAHA.122.321253

  • 123

    ChenLIshigamiTNakashima-SasakiRKinoTDoiHMinegishiSet al. Commensal microbe-specific activation of B2 cell subsets contributes to atherosclerosis development independently of lipid metabolism. EBioMedicine. (2016) 13:237–47. doi: 10.1016/j.ebiom.2016.10.030

  • 124

    SaitaDFerrareseRFoglieniCEspositoACanuTPeraniLet al. Adaptive immunity against gut microbiota enhances apoE-mediated immune regulation and reduces atherosclerosis and western-diet-related inflammation. Sci Rep. (2016) 6:29353. doi: 10.1038/srep29353

  • 125

    PindjakovaJSartiniCLo ReORappaFCoupeBLelouvierBet al. Gut dysbiosis and adaptive immune response in diet-induced obesity vs. Systemic Inflammation. Front Microbiol. (2017) 8:1157. doi: 10.3389/fmicb.2017.01157

  • 126

    LauransLMouttoulingamNChajadineMLavelleADiedisheimMBacquerEet al. An obesogenic diet increases atherosclerosis through promoting microbiota dysbiosis-induced gut lymphocyte trafficking into the periphery. Cell Rep. (2023) 42:113350. doi: 10.1016/j.celrep.2023.113350

  • 127

    WilhelmAJMajorAS. Accelerated atherosclerosis in SLE: mechanisms and prevention approaches. Int J Clin Rheumtol. (2012) 7:527–39. doi: 10.2217/ijr.12.46

  • 128

    TuHLiQXiangSJiangHMaoYShouZet al. Dual effects of statins therapy in systemic lupus erythematosus and SLE-related atherosclerosis: the potential role for regulatory T cells. Atherosclerosis. (2012) 222:29–33. doi: 10.1016/j.atherosclerosis.2012.02.023

  • 129

    de JongHJTervaertJWSaldiSRVandebrielRJSouvereinPCMeyboomRHet al. Association between statin use and lupus-like syndrome using spontaneous reports. Semin Arthritis Rheum. (2011) 41:373–81. doi: 10.1016/j.semarthrit.2011.06.002

  • 130

    De JongHJIvan StaaTPLalmohamedAde VriesFVandebrielRJVan LoverenHet al. Pattern of risks of systemic lupus erythematosus among statin users: a population-based cohort study. Ann Rheum Dis. (2017) 76:1723–30. doi: 10.1136/annrheumdis-2016-210936

  • 131

    PetriMAKianiANPostWChristopher-StineLMagderLS. Lupus atherosclerosis prevention study (LAPS). Ann Rheum Dis. (2011) 70:760–5. doi: 10.1136/ard.2010.136762

  • 132

    MacLeodCHadokePWFNixonM. Glucocorticoids: fuelling the fire of atherosclerosis or therapeutic extinguishers? Int J Mol Sci. (2021) 22:7622. doi: 10.3390/ijms22147622

  • 133

    BlachutDPrzywara-ChowaniecBHarpulaJTomasikANowalany-KozielskaEMorawiecB. The effects of glucocorticoid treatment on cardiovascular system in patients with systemic lupus erythematosus. Arch Rheumatol. (2022) 37:495–503. doi: 10.46497/ArchRheumatol.2022.9255

  • 134

    Mejia-ViletJMAyoubI. The use of glucocorticoids in lupus nephritis: new pathways for an old drug. Front Med (Lausanne). (2021) 8:622225. doi: 10.3389/fmed.2021.622225

  • 135

    RichezCRichardsRJDuffauPWeitznerZAndryCDRifkinIRet al. The effect of mycophenolate mofetil on disease development in the gld.apoE (-/-) mouse model of accelerated atherosclerosis and systemic lupus erythematosus. PLoS One. (2013) 8:e61042. doi: 10.1371/journal.pone.0061042

  • 136

    Sato-OkabayashiYIsodaKHeissigBKadoguchiTAkitaKKitamuraKet al. Low-dose oral cyclophosphamide therapy reduces atherosclerosis progression by decreasing inflammatory cells in a murine model of atherosclerosis. Int J Cardiol Heart Vasc. (2020) 28:100529. doi: 10.1016/j.ijcha.2020.100529

  • 137

    McMahonMSkaggsBGrossmanJWongWKSahakianLChenWet al. Comparison of PREDICTS atherosclerosis biomarker changes after initiation of new treatments in patients with SLE. Lupus Sci Med. (2019) 6:e000321. doi: 10.1136/lupus-2019-000321

  • 138

    van LeuvenSIvan WijkDFVolgerOLde VriesJPvan der LoosCMde KleijnDVet al. Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis. Atherosclerosis. (2010) 211:231–6. doi: 10.1016/j.atherosclerosis.2010.01.043

  • 139

    KianiANMagderLSPetriM. Mycophenolate mofetil (MMF) does not slow the progression of subclinical atherosclerosis in SLE over 2 years. Rheumatol Int. (2012) 32:2701–5. doi: 10.1007/s00296-011-2048-y

  • 140

    FlorisAPigaMMangoniAABortoluzziAErreGLCauliA. Protective effects of hydroxychloroquine against accelerated atherosclerosis in systemic lupus erythematosus. Mediators Inflammation. (2018) 2018:3424136. doi: 10.1155/2018/3424136

  • 141

    LeeHHanJHKimSKimSChoDHWooCH. Anti-malarial drugs reduce vascular smooth muscle cell proliferation via activation of AMPK and inhibition of smad3 signaling. J Lipid Atheroscler. (2019) 8:267–76. doi: 10.12997/jla.2019.8.2.267

  • 142

    UlanderLSimonenPTolppanenHHartmanORissanenTTEklundKKet al. The effect of hydroxychloroquine on cholesterol metabolism in statin treated patients after myocardial infarction. Atheroscler Plus. (2023) 53:26–32. doi: 10.1016/j.athplu.2023.06.003

  • 143

    Rua-FigueroaIRua-FigueroaDPerez-VeigaNAnzolaAMGalindo-IzquierdoMCalvo-AlenJet al. Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure. Semin Arthritis Rheum. (2022) 52:151946. doi: 10.1016/j.semarthrit.2021.11.012

  • 144

    YangDHLeongPYSiaSKWangYHWeiJC. Long-term hydroxychloroquine therapy and risk of coronary artery disease in patients with systemic lupus erythematosus. J Clin Med. (2019) 8:796. doi: 10.3390/jcm8060796

  • 145

    LiuDLiXZhangYKwongJSLiLZhangYet al. Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis. Drug Des Devel Ther. (2018) 12:1685–95. doi: 10.2147/DDDT.S166893

  • 146

    FurieRKhamashtaMMerrillJTWerthVPKalunianKBrohawnPet al. Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. (2017) 69:376–86. doi: 10.1002/art.39962

  • 147

    KnightJSSubramanianVO’DellAAYalavarthiSZhaoWSmithCKet al. Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice. Ann Rheum Dis. (2015) 74:2199–206. doi: 10.1136/annrheumdis-2014-205365

  • 148

    RichterPCardoneanuABurluiAMMacoveiLABratoiuIBuliga-FinisONet al. Why do we need JAK inhibitors in systemic lupus erythematosus? Int J Mol Sci. (2022) 23:11788. doi: 10.3390/ijms231911788

  • 149

    HasniSAGuptaSDavisMPoncioETemesgen-OyelakinYCarlucciPMet al. Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun. (2021) 12:3391. doi: 10.1038/s41467-021-23361-z

  • 150

    FurumotoYSmithCKBlancoLZhaoWBrooksSRThackerSGet al. Tofacitinib ameliorates murine lupus and its associated vascular dysfunction. Arthritis Rheumatol. (2017) 69:148–60. doi: 10.1002/art.39818

  • 151

    FoksACLichtmanAHKuiperJ. Treating atherosclerosis with regulatory T cells. Arterioscler Thromb Vasc Biol. (2015) 35:280–7. doi: 10.1161/ATVBAHA.114.303568

  • 152

    HeJZhangXWeiYSunXChenYDengJet al. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. Nat Med. (2016) 22:991–3. doi: 10.1038/nm.4148

  • 153

    MockelTBastaFWeinmann-MenkeJSchwartingA. B cell activating factor (BAFF): Structure, functions, autoimmunity and clinical implications in Systemic Lupus Erythematosus (SLE). Autoimmun Rev. (2021) 20:102736. doi: 10.1016/j.autrev.2020.102736

  • 154

    SaidouneFEvenGLamriYChezelJGastonATEscoubetBet al. Effects of BAFF neutralization on atherosclerosis associated with systemic lupus erythematosus. Arthritis Rheumatol. (2021) 73:255–64. doi: 10.1002/art.41485

  • 155

    LiangDHuangSDingR. Effects of belimumab on the lipid profile in systemic lupus erythematosus patients: an observational study. Clin Rheumatol. (2024) 43:2513–20. doi: 10.1007/s10067-024-07029-9

  • 156

    Ait-OufellaHHerbinOBouazizJDBinderCJUyttenhoveCLauransLet al. B cell depletion reduces the development of atherosclerosis in mice. J Exp Med. (2010) 207:1579–87. doi: 10.1084/jem.20100155

  • 157

    KridinKMruwatNLudwigRJ. Association of rituximab with risk of long-term cardiovascular and metabolic outcomes in patients with pemphigus. JAMA Dermatol. (2023) 159:56–61. doi: 10.1001/jamadermatol.2022.5182

  • 158

    VlacilAKSchuettJRuppertVSoufiMOberoiRShahinKet al. Deficiency of Nucleotide-binding oligomerization domain-containing proteins (NOD) 1 and 2 reduces atherosclerosis. Basic Res Cardiol. (2020) 115:47. doi: 10.1007/s00395-020-0806-2

  • 159

    YoshidaNEmotoTYamashitaTWatanabeHHayashiTTabataTet al. Bacteroides vulgatus and Bacteroides dorei Reduce Gut Microbial Lipopolysaccharide Production and Inhibit Atherosclerosis. Circulation. (2018) 138:2486–98. doi: 10.1161/CIRCULATIONAHA.118.033714

  • 160

    KasaharaKKrautkramerKAOrgERomanoKAKerbyRLVivasEIet al. Interactions between Roseburia intestinalis and diet modulate atherogenesis in a murine model. Nat Microbiol. (2018) 3:1461–71. doi: 10.1038/s41564-018-0272-x

  • 161

    ChanYKBrarMSKirjavainenPVChenYPengJLiDet al. High fat diet induced atherosclerosis is accompanied with low colonic bacterial diversity and altered abundances that correlates with plaque size, plasma A-FABP and cholesterol: a pilot study of high fat diet and its intervention with Lactobacillus rhamnosus GG (LGG) or telmisartan in ApoE(-/-) mice. BMC Microbiol. (2016) 16:264. doi: 10.1186/s12866-016-0883-4

  • 162

    LiuSJFuJJLiaoZYLiuYXHeJHeLYet al. Z-ligustilide alleviates atherosclerosis by reconstructing gut microbiota and sustaining gut barrier integrity through activation of cannabinoid receptor 2. Phytomedicine. (2024) 135:156117. doi: 10.1016/j.phymed.2024.156117

  • 163

    HaoHLiZQiaoSYQiYXuXYSiJYet al. Empagliflozin ameliorates atherosclerosis via regulating the intestinal flora. Atherosclerosis. (2023) 371:32–40. doi: 10.1016/j.atherosclerosis.2023.03.011

  • 164

    KimESYoonBHLeeSMChoiMKimEHLeeBWet al. Fecal microbiota transplantation ameliorates atherosclerosis in mice with C1q/TNF-related protein 9 genetic deficiency. Exp Mol Med. (2022) 54:103–14. doi: 10.1038/s12276-022-00728-w

  • 165

    LiZHWengJYanJZengYHHaoQYShengHFet al. Puerarin alleviates atherosclerosis via the inhibition of Prevotella copri and its trimethylamine production. Gut. (2024) 73:1934–43. doi: 10.1136/gutjnl-2024-331880

  • 166

    MaSRTongQLinYPanLBFuJPengRet al. Berberine treats atherosclerosis via a vitamine-like effect down-regulating Choline-TMA-TMAO production pathway in gut microbiota. Signal Transduct Target Ther. (2022) 7:207. doi: 10.1038/s41392-022-01027-6

  • 167

    WangXCuiJGuZGuoLLiuRGuoYet al. Aged garlic oligosaccharides modulate host metabolism and gut microbiota to alleviate high-fat and high-cholesterol diet-induced atherosclerosis in ApoE(-/-) mice. Food Chem. (2025) 463:141409. doi: 10.1016/j.foodchem.2024.141409

  • 168

    JiangCWangSWangYWangKHuangCGaoFet al. Polyphenols from hickory nut reduce the occurrence of atherosclerosis in mice by improving intestinal microbiota and inhibiting trimethylamine N-oxide production. Phytomedicine. (2024) 128:155349. doi: 10.1016/j.phymed.2024.155349

  • 169

    LuoZYangLZhuTFanFWangXLiuYet al. Aucubin ameliorates atherosclerosis by modulating tryptophan metabolism and inhibiting endothelial-mesenchymal transitions via gut microbiota regulation. Phytomedicine. (2024) 135:156122. doi: 10.1016/j.phymed.2024.156122

  • 170

    HeYZhuYShuiXHuangZLiKLeiW. Gut microbiome and metabolomic profiles reveal the antiatherosclerotic effect of indole-3-carbinol in high-choline-fed ApoE(-/-) mice. Phytomedicine. (2024) 129:155621. doi: 10.1016/j.phymed.2024.155621

  • 171

    HaghikiaAZimmermannFSchumannPJasinaARoesslerJSchmidtDet al. Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism. Eur Heart J. (2022) 43:518–33. doi: 10.1093/eurheartj/ehab644

  • 172

    VikramAKimYRKumarSLiQKassanMJacobsJSet al. Vascular microRNA-204 is remotely governed by the microbiome and impairs endothelium-dependent vasorelaxation by downregulating Sirtuin1. Nat Commun. (2016) 7:12565. doi: 10.1038/ncomms12565

  • 173

    LiXLCuiJJZhengWSZhangJLLiRMaXLet al. Bicyclol alleviates atherosclerosis by manipulating gut microbiota. Small. (2022) 18:e2105021. doi: 10.1002/smll.202105021

  • 174

    YangXYYuHFuJGuoHHHanPMaSRet al. Hydroxyurea ameliorates atherosclerosis in ApoE(-/-) mice by potentially modulating Niemann-Pick C1-like 1 protein through the gut microbiota. Theranostics. (2022) 12:7775–87. doi: 10.7150/thno.76805

  • 175

    WangAGuanBYuLLiuQHouYLiZet al. Palmatine protects against atherosclerosis by gut microbiota and phenylalanine metabolism. Pharmacol Res. (2024) 209:107413. doi: 10.1016/j.phrs.2024.107413

  • 176

    XuMLvCWangHLuQYeMZhuXet al. Peanut skin extract ameliorates high-fat diet-induced atherosclerosis by regulating lipid metabolism, inflammation reaction and gut microbiota in ApoE(-/-) mice. Food Res Int. (2022) 154:111014. doi: 10.1016/j.foodres.2022.111014

  • 177

    WangYWuJHongYZhuJZhangYZhangJet al. Ginsenosides retard atherogenesis via remodelling host-microbiome metabolic homeostasis. Br J Pharmacol. (2024) 181:1768–92. doi: 10.1111/bph.16320

  • 178

    LuCLiuDWuQZengJXiongYLuoT. EphA2 blockage ALW-II-41–27 alleviates atherosclerosis by remodeling gut microbiota to regulate bile acid metabolism. NPJ Biofilms Microbiomes. (2024) 10:108. doi: 10.1038/s41522-024-00585-7

  • 179

    TraughberCATiminskiKPrinceABhandariNNeupaneKKhanMRet al. Disulfiram reduces atherosclerosis and enhances efferocytosis, autophagy, and atheroprotective gut microbiota in hyperlipidemic mice. J Am Heart Assoc. (2024) 13:e033881. doi: 10.1161/JAHA.123.033881

  • 180

    MoleonJGonzalez-CorreaCRobles-VeraIMinanoSde la VisitacionNBarrancoAMet al. Targeting the gut microbiota with dietary fibers: a novel approach to prevent the development cardiovascular complications linked to systemic lupus erythematosus in a preclinical study. Gut Microbes. (2023) 15:2247053. doi: 10.1080/19490976.2023.2247053

Summary

Keywords

systemic lupus erythematosus, atherosclerosis, immune dysregulation, gut microbiome imbalance, metabolic disorders

Citation

Pan Q, Huang X, Liu C, Pan Q and Huang S (2025) Systemic lupus erythematosus and atherosclerosis: immune pathways and the uncharted territory of gut microbiota and metabolism. Front. Immunol. 16:1492726. doi: 10.3389/fimmu.2025.1492726

Received

07 September 2024

Accepted

07 April 2025

Published

28 April 2025

Volume

16 - 2025

Edited by

Kim Maree O’Sullivan, Monash University, Australia

Reviewed by

Daming Zuo, Southern Medical University, China

Simona Rolla, University of Turin, Italy

Patricia López, University of Oviedo, Spain

Updates

Copyright

© 2025 Pan, Huang, Liu, Pan and Huang.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Qingjun Pan, ; Shian Huang,

†These authors have contributed equally to this work

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Share on WeChat

Scan with WeChat to share this article

Article metrics